Literature DB >> 22427351

Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells.

Magali Terme1, Evelyn Ullrich, Laetitia Aymeric, Kathrin Meinhardt, Jérôme D Coudert, Mélanie Desbois, François Ghiringhelli, Sophie Viaud, Bernard Ryffel, Hideo Yagita, Lieping Chen, Salaheddine Mécheri, Gilles Kaplanski, Armelle Prévost-Blondel, Masashi Kato, Joachim L Schultze, Eric Tartour, Guido Kroemer, Mariapia Degli-Esposti, Nathalie Chaput, Laurence Zitvogel.   

Abstract

During cancer development, a number of regulatory cell subsets and immunosuppressive cytokines subvert adaptive immune responses. Although it has been shown that tumor-derived interleukin (IL)-18 participates in the PD-1-dependent tumor progression in NK cell-controlled cancers, the mechanistic cues underlying this immunosuppression remain unknown. Here, we show that IL-18 converts a subset of Kit(-) (CD11b(-)) into Kit(+) natural killer (NK) cells, which accumulate in all lymphoid organs of tumor bearers and mediate immunoablative functions. Kit(+) NK cells overexpressed B7-H1/PD-L1, a ligand for PD-1. The adoptive transfer of Kit(+) NK cells promoted tumor growth in two pulmonary metastases tumor models and significantly reduced the dendritic and NK cell pools residing in lymphoid organs in a B7-H1-dependent manner. Neutralization of IL-18 by RNA interference in tumors or systemically by IL-18-binding protein dramatically reduced the accumulation of Kit(+)CD11b(-) NK cells in tumor bearers. Together, our findings show that IL-18 produced by tumor cells elicits Kit(+)CD11b(-) NK cells endowed with B7-H1-dependent immunoablative functions in mice. ©2012 AACR

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22427351     DOI: 10.1158/0008-5472.CAN-11-3379

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

Review 1.  Alterations in macrophages and monocytes from tumor-bearing mice: evidence of local and systemic immune impairment.

Authors:  Marta Torroella-Kouri; Dayron Rodríguez; Raul Caso
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

2.  The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector.

Authors:  Wenjuan Dong; Xiaojin Wu; Shoubao Ma; Yufeng Wang; Ansel P Nalin; Zheng Zhu; Jianying Zhang; Don M Benson; Kai He; Michael A Caligiuri; Jianhua Yu
Journal:  Cancer Discov       Date:  2019-07-24       Impact factor: 39.397

Review 3.  Challenges of NK cell-based immunotherapy in the new era.

Authors:  Fang Fang; Weihua Xiao; Zhigang Tian
Journal:  Front Med       Date:  2018-07-25       Impact factor: 4.592

4.  Interleukin-17D mediates tumor rejection through recruitment of natural killer cells.

Authors:  Timothy O'Sullivan; Robert Saddawi-Konefka; Emilie Gross; Miller Tran; Stephen P Mayfield; Hiroaki Ikeda; Jack D Bui
Journal:  Cell Rep       Date:  2014-05-01       Impact factor: 9.423

5.  Deficiency of IL-18 Aggravates Esophageal Carcinoma Through Inhibiting IFN-γ Production by CD8+T Cells and NK Cells.

Authors:  Jiantao Li; Gang Qiu; Baoshuan Fang; Xiaohui Dai; Jianhui Cai
Journal:  Inflammation       Date:  2018-03       Impact factor: 4.092

6.  Bone marrow-derived dendritic cells under influence of experimental breast cancer and physical activity.

Authors:  Douglas R Abdalla; Bruno B M Gomes; Eddie F C Murta; Márcia A Michelin
Journal:  Oncol Lett       Date:  2017-01-11       Impact factor: 2.967

7.  Linking cancer-induced Nlrp3 inflammasome activation to efficient NK cell-mediated immunosurveillance.

Authors:  Maryse Dagenais; Maya Saleh
Journal:  Oncoimmunology       Date:  2016-04-22       Impact factor: 8.110

8.  Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAFV600E melanoma.

Authors:  Shin Foong Ngiow; Katrina M Meeth; Kimberley Stannard; Deborah S Barkauskas; Gideon Bollag; Marcus Bosenberg; Mark J Smyth
Journal:  Oncoimmunology       Date:  2015-12-10       Impact factor: 8.110

9.  IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment.

Authors:  Jeffrey L Wong; Erik Berk; Robert P Edwards; Pawel Kalinski
Journal:  Cancer Res       Date:  2013-06-12       Impact factor: 12.701

Review 10.  Insight to drug delivery aspects for colorectal cancer.

Authors:  Arvind Gulbake; Aviral Jain; Ashish Jain; Ankit Jain; Sanjay K Jain
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.